Pluristem Therapeutics Inc. (PSTI) reports treatment of COVID-19 patient
Pluristem Therapeutics Inc. (PSTI) currently trades at $8.31 and has grown by 19% today. PSTI went up $1.33 from the previous closing price of $6.97. The high forecast for Pluristem Therapeutics Inc. is $25.00 and the low is $8.00. The company’s market cap is $148.43 million with a 52 week high of $9.55 and a 52 week low of $2.82. PSTI has changed in price by 2.05 per share in the last 12 months. The company announced today that it has treated its first patient suffering from COVID-19 complications in the United States under the U.S. Food and Drug Administration’s (FDA). The patient was treated with PLX cell therapy at Holy Name Medical Center in New Jersey. The patient was critically ill with respiratory failure due to acute respiratory distress syndrome (ARDS) and was under mechanical ventilation in an intensive care unit (ICU) for three weeks.
Pluristem Therapeutics Inc. has a weak EPS of -2.17. This means the company lost $-2.17 per share after paying dividends, this can indicate that the stock is a risky investment. EPS is calculated as a company’s profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company’s profitability. It is common for a company to report EPS that is adjusted for extraordinary items and potential share dilution. Based on this information, investorsQ rates this stock 5 out of 10. We give it this rating based on current information written in this article.
About Pluristem Therapeutics Inc.:
Pluristem Therapeutics Inc. is a clinical-stage biotherapy company using placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for conditions such as inflammation, ischemia, muscle injuries, hematological disorders and exposure to radiation.